Active ingredients: fluticasone furoate + vilanterol
What it is used for
Asthma,Breo Ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,Vilanterol, an active ingredient in Breo Ellipta, is a long-acting beta-2-agonist (LABA). A class effect of all LABAs can be an increased risk of asthma death (see Precautions).
How to take it
The way to take this medicine is: Inhalation.
- Store below 30 degrees Celsius
- See Product information for shelf life
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
A plastic inhaler with light grey body, pale blue mouthpiece cover and a dose counter, containing two strips of blisters each containing a white powder
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient fluticasone furoate + vilanterol
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems